Biogen Inc

Company Profile

• Business description

  Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

• Contact

  225 Binney Street
  CambridgeMA02142
  USA

  T: +1 617 679-2000

  E: [email protected]

  https://www.biogen.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Drug Manufacturers - General

  Fiscal Year End

  31 December 2025

  Employees

  7,605